Market Cap | 20.32M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -19.9M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -14.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -37.00% |
Dividend | N/A | Price/Book | 7.64 | EPS next 5Y | - | 52W High Chg | -87.00% |
Recommedations | - | Quick Ratio | 2.22 | Shares Outstanding | 14.62M | 52W Low Chg | 10.00% |
Insider Own | 78.95% | ROA | -298.41% | Shares Float | 2.37M | Beta | - |
Inst Own | 1.27% | ROE | - | Shares Shorted/Prior | 648.12K/621.89K | Price | 1.39 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,090,280 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 296,783 | Change | -1.42% |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Weisman Howard J. | Chief Executive Offi.. Chief Executive Officer | Mar 08 | Sell | 1.45 | 35,892 | 52,043 | 541,633 | 03/09/23 |
Rome Zachary | Chief Operating Offi.. Chief Operating Officer | Mar 08 | Sell | 1.46 | 33,405 | 48,771 | 288,452 | 03/09/23 |
Derby Michael | Executive Chairman Executive Chairman | Mar 09 | Sell | 1.43 | 2,143 | 3,064 | 324,430 | 03/09/23 |
LaRochelle Karen | Director Director | Mar 09 | Sell | 1.48 | 335 | 496 | 42,415 | 03/09/23 |
Coelho John F | Director Director | Mar 09 | Sell | 1.48 | 130 | 192 | 67,235 | 03/09/23 |
Weisman Howard J. | Chief Executive Offi.. Chief Executive Officer | Mar 06 | Sell | 1.63 | 37,140 | 60,538 | 577,525 | 03/07/23 |
Rome Zachary | Chief Operating Offi.. Chief Operating Officer | Mar 06 | Sell | 1.63 | 36,992 | 60,297 | 321,857 | 03/07/23 |
Derby Michael | Executive Chairman Executive Chairman | Mar 06 | Sell | 1.64 | 28,962 | 47,498 | 326,573 | 03/07/23 |
Coelho John F | Director Director | Mar 02 | Sell | 1.93 | 3,013 | 5,815 | 67,365 | 03/03/23 |
LaRochelle Karen | Director Director | Mar 02 | Sell | 1.92 | 8,833 | 16,959 | 42,750 | 03/03/23 |
Weisman Howard J. | Chief Executive Offi.. Chief Executive Officer | Mar 02 | Sell | 1.92 | 27,002 | 51,844 | 614,665 | 03/03/23 |
Rome Zachary | Chief Operating Offi.. Chief Operating Officer | Mar 02 | Sell | 1.92 | 26,151 | 50,210 | 358,849 | 03/03/23 |
Derby Michael | Executive Chairman Executive Chairman | Mar 02 | Sell | 1.92 | 29,465 | 56,573 | 355,535 | 03/03/23 |